Understanding and regulating autoimmune disease through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) family transcription factor, RelB (2009–2013)

This programme of work seeks to develop antigen-specific treatment for human autoimmune disease - a major knowledge gap and medical need. The programme spans innovative research into mouse models of autoimmunity and tolerance, studies of dendritic cell activity in patient populations and autoimmune disease susceptibility, and design of immunotherapeutic solutions applicable to human disease in mouse models and early phase clinical trials. The major expected outcomes are proof-of-concept for the first antigen-specific immunotherapy for rheumatoid arthritis, and identification of a patient population suitable for immunotherapy for type 1 diabetes, validated in mouse models.
Grant type:
ARC Future Fellowships
Funded by:
Australian Research Council